Trials for moderate-to-severe psoriasis demonstrate a durable response to bimekizumab after four years.

Published Date: 20 Mar 2024

According to studies presented at the annual meeting of, patients with psoriasis treated with bimekizumab quickly achieve high levels of clinical and health-related quality-of-life responses that are sustained at four years.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Sub-Q Ketamine is Safe and Very Effective for Severe Depression.

2.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

3.

Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.

4.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

5.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot